Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
Background: forgiveness is the ability of a given regimen to maintain complete viral suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide. Methods: drug refills were used to calculate the percent day covered (PDC) as a proxy...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-11-01
|
| Series: | Journal of the International Association of Providers of AIDS Care |
| Online Access: | https://doi.org/10.1177/23259582221140208 |
| _version_ | 1797988184671387648 |
|---|---|
| author | Franco Maggiolo Daniela Valenti Rodolfo Teocchi Laura Comi Elisa Di Filippo Marco Rizzi |
| author_facet | Franco Maggiolo Daniela Valenti Rodolfo Teocchi Laura Comi Elisa Di Filippo Marco Rizzi |
| author_sort | Franco Maggiolo |
| collection | DOAJ |
| description | Background: forgiveness is the ability of a given regimen to maintain complete viral suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide. Methods: drug refills were used to calculate the percent day covered (PDC) as a proxy of adherence. Forgiveness was calculated as the achieved rate of a selected HIV-RNA threshold by a given level of imperfect adherence. Results: 281 adult PLWH were followed for 343 patient/years. Adherence was very high with a median of 98% (IQR 95-100%). A PDC as low as 70% was sufficient to obtain 100% and maintain virologic suppression. According to probit analysis adherence was not related to the possibility to maintain an HIV-RNA TND or < 50 copies/ml. Conclusions: Long-term success of ART needs effective regimens that are the least intrusive of the patient's lifestyle, an elevated forgiveness may be considered as an additional feature that can further improve long-term outcomes. |
| first_indexed | 2024-04-11T07:58:47Z |
| format | Article |
| id | doaj.art-08ee674a076945f391fea51ef72fbd26 |
| institution | Directory Open Access Journal |
| issn | 2325-9582 |
| language | English |
| last_indexed | 2024-04-11T07:58:47Z |
| publishDate | 2022-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of the International Association of Providers of AIDS Care |
| spelling | doaj.art-08ee674a076945f391fea51ef72fbd262022-12-22T04:35:48ZengSAGE PublishingJournal of the International Association of Providers of AIDS Care2325-95822022-11-012110.1177/23259582221140208Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir AlafenamideFranco Maggiolo0Daniela Valenti1Rodolfo Teocchi2Laura Comi3Elisa Di Filippo4Marco Rizzi5 UOC Infectious Diseases, ASST Papa Giovanni XXII, Bergamo, Italy FROM foundation, ASST Papa Giovanni XXII, Bergamo, Italy Informatics department, ASST Papa Giovanni XXII, Bergamo, Italy UOC Infectious Diseases, ASST Papa Giovanni XXII, Bergamo, Italy UOC Infectious Diseases, ASST Papa Giovanni XXII, Bergamo, Italy UOC Infectious Diseases, ASST Papa Giovanni XXII, Bergamo, ItalyBackground: forgiveness is the ability of a given regimen to maintain complete viral suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide. Methods: drug refills were used to calculate the percent day covered (PDC) as a proxy of adherence. Forgiveness was calculated as the achieved rate of a selected HIV-RNA threshold by a given level of imperfect adherence. Results: 281 adult PLWH were followed for 343 patient/years. Adherence was very high with a median of 98% (IQR 95-100%). A PDC as low as 70% was sufficient to obtain 100% and maintain virologic suppression. According to probit analysis adherence was not related to the possibility to maintain an HIV-RNA TND or < 50 copies/ml. Conclusions: Long-term success of ART needs effective regimens that are the least intrusive of the patient's lifestyle, an elevated forgiveness may be considered as an additional feature that can further improve long-term outcomes.https://doi.org/10.1177/23259582221140208 |
| spellingShingle | Franco Maggiolo Daniela Valenti Rodolfo Teocchi Laura Comi Elisa Di Filippo Marco Rizzi Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide Journal of the International Association of Providers of AIDS Care |
| title | Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide |
| title_full | Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide |
| title_fullStr | Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide |
| title_full_unstemmed | Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide |
| title_short | Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide |
| title_sort | real world data on forgiveness to uncomplete adherence to bictegravir emtricitabine tenofovir alafenamide |
| url | https://doi.org/10.1177/23259582221140208 |
| work_keys_str_mv | AT francomaggiolo realworlddataonforgivenesstouncompleteadherencetobictegraviremtricitabinetenofoviralafenamide AT danielavalenti realworlddataonforgivenesstouncompleteadherencetobictegraviremtricitabinetenofoviralafenamide AT rodolfoteocchi realworlddataonforgivenesstouncompleteadherencetobictegraviremtricitabinetenofoviralafenamide AT lauracomi realworlddataonforgivenesstouncompleteadherencetobictegraviremtricitabinetenofoviralafenamide AT elisadifilippo realworlddataonforgivenesstouncompleteadherencetobictegraviremtricitabinetenofoviralafenamide AT marcorizzi realworlddataonforgivenesstouncompleteadherencetobictegraviremtricitabinetenofoviralafenamide |